{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:37:55Z","timestamp":1786736275492,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Indian Assoc Pediatr Surg"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/jiaps.jiaps_12_18","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T05:09:24Z","timestamp":1559797764000},"page":"170","source":"Crossref","is-referenced-by-count":8,"title":["Oral propranolol in infantile hemangiomas: Analysis of factors that affect the outcome"],"prefix":"10.4103","volume":"24","author":[{"given":"SarathKumar","family":"Narayanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ArunMohanan","family":"Ainipully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ArunPreeth","family":"Vazhiyodan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prathap","family":"Somnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0971-9261.259751-1","first-page":"894","volume-title":"Congenital vascular lesions: Clinical application of a new classification","author":"Finn","year":"1983","journal-title":"J Pediatr Surg"},{"key":"key-10.4103\/0971-9261.259751-2","first-page":"159","volume-title":"Treatment for infantile hemangiomas: Selection criteria, safety, and outcomes using oral propranolol during the early phase of propranolol use for hemangiomas","author":"MacIsaac","year":"2016","journal-title":"J Craniofac Surg"},{"key":"key-10.4103\/0971-9261.259751-3","first-page":"707","volume-title":"Propranolol treatment of infantile hemangioma: Clinical and radiologic evaluations","author":"Talaat","year":"2012","journal-title":"J Pediatr Surg"},{"key":"key-10.4103\/0971-9261.259751-4","first-page":"284","volume-title":"Oral propranolol for infantile hemangioma","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0971-9261.259751-5","first-page":"759","volume-title":"Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution","author":"Itinteang","year":"2011","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"key-10.4103\/0971-9261.259751-6","first-page":"1254","volume-title":"Infantile haemangioma: Part II.Risks, complications and treatment","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0971-9261.259751-7","first-page":"1301","volume-title":"Management of hemangioma of infancy: Review of 245 patients","author":"Achauer","year":"1997","journal-title":"Plast Reconstr Surg"},{"key":"key-10.4103\/0971-9261.259751-8","first-page":"2649","volume-title":"Propranolol for severe hemangiomas of infancy","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0971-9261.259751-9","first-page":"610","volume-title":"Propranolol treatment for hemangioma of infancy: Risks and recommendations","author":"Lawley","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"key-10.4103\/0971-9261.259751-10","first-page":"99","volume-title":"Infantile hemangiomas: An update on pathogenesis and therapy","author":"Chen","year":"2013","journal-title":"Pediatrics"},{"key":"key-10.4103\/0971-9261.259751-11","first-page":"640","volume-title":"Propranolol therapy in 55 infants with infantile hemangioma: Dosage, duration, adverse effects, and outcome","author":"Schupp","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"key-10.4103\/0971-9261.259751-12","first-page":"813","volume-title":"Evaluating systemic prednisone therapy for proliferating haemangioma in infancy","author":"R\u00f6ssler","year":"2008","journal-title":"Eur J Pediatr"},{"key":"key-10.4103\/0971-9261.259751-13","first-page":"e259","volume-title":"A randomized controlled trial of propranolol for infantile hemangiomas","author":"Hogeling","year":"2011","journal-title":"Pediatrics"},{"key":"key-10.4103\/0971-9261.259751-14","unstructured":"Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol for Infantile Hemangiomas: A Meta Analysis. Monterey, CA: Poster at the Society for Pediatric Dermatology Annual Meeting; July, 2012."},{"key":"key-10.4103\/0971-9261.259751-15","first-page":"125","volume-title":"Treatment with propranolol for infantile hemangioma in 13 Taiwanese newborns and young infants","author":"Hsu","year":"2012","journal-title":"Pediatr Neonatol"},{"key":"key-10.4103\/0971-9261.259751-16","first-page":"25","volume-title":"Therapeutic effect of propranolol in Mexican patients with infantile hemangioma","author":"Castaneda","year":"2016","journal-title":"Drugs Real World Outcomes"},{"key":"key-10.4103\/0971-9261.259751-17","first-page":"342","volume-title":"Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck","author":"Dong","year":"2017","journal-title":"Sci Rep"},{"key":"key-10.4103\/0971-9261.259751-18","first-page":"269","volume-title":"Propranolol for infantile haemangiomas: Insights into the molecular mechanisms of action","author":"Storch","year":"2010","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0971-9261.259751-19","first-page":"902","volume-title":"Use of propranolol for treatment of infantile haemangiomas in an outpatient setting","author":"Phillips","year":"2012","journal-title":"J Paediatr Child Health"},{"key":"key-10.4103\/0971-9261.259751-20","first-page":"A4776","volume-title":"Effectiveness of propanolol for treatment of infantile haemangioma","author":"Andersen","year":"2014","journal-title":"Dan Med J"},{"key":"key-10.4103\/0971-9261.259751-21","first-page":"48","volume-title":"Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell","author":"Zhang","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"key-10.4103\/0971-9261.259751-22","first-page":"837","volume-title":"Propranolol in a case series of 174 patients with complicated infantile haemangioma: Indications, safety and future directions","author":"Hermans","year":"2013","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0971-9261.259751-23","first-page":"1371","volume-title":"Propranolol vs.corticosteroids for infantile hemangiomas: A multicenter retrospective analysis","author":"Price","year":"2011","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0971-9261.259751-24","first-page":"1643","volume-title":"Untreated hemangiomas: Growth pattern and residual lesions","author":"Bauland","year":"2011","journal-title":"Plast Reconstr Surg"}],"container-title":["Journal of Indian Association of Pediatric Surgeons"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:39:50Z","timestamp":1786732790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jiaps.JIAPS_12_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"alternative-id":["259751"],"URL":"https:\/\/doi.org\/10.4103\/jiaps.jiaps_12_18","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736421298.793567318","asserted-by":"object"}]},"ISSN":["0971-9261"],"issn-type":[{"value":"0971-9261","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}